G.J. Lockbaum

729 citations

21 papers · 448 indexed · h-index 13

Impact in

Virology top 5%
- HIV Research and Treatment
Infectious Diseases top 5%
- SARS-CoV-2 and COVID-19 Research
- HIV/AIDS drug development and treatment

Papers in ⓘ

Infectious Diseases 14
- HIV/AIDS drug development and treatment 10
- SARS-CoV-2 and COVID-19 Research 4
Molecular Biology 9
- RNA and protein synthesis mechanisms 4

Co-authors: Celia A. Schiffer (18 shared papers)Neşe Kurt Yılmaz (16 shared papers)E.A. Nalivaika (11 shared papers)Akbar Ali (11 shared papers)M. Henes (12 shared papers)Paul R. Thompson (3 shared papers)L.N. Rusere (7 shared papers)Archie C. Reyes (2 shared papers)
Journals: ACS Medicinal Chemistry Letters (2 papers)Molecular Cancer Therapeutics (2 papers)Nature Communications (2 papers)Biochemistry (2 papers)Journal of Medicinal Chemistry (2 papers)
Partner nations: United States

In The Last Decade

G.J. Lockbaum

20 papers receiving 443 citations

Peers

Countries citing papers authored by G.J. Lockbaum

Since Specialization

Citations

This map shows the geographic impact of G.J. Lockbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G.J. Lockbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G.J. Lockbaum more than expected).

Fields of papers citing papers by G.J. Lockbaum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G.J. Lockbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G.J. Lockbaum. The network helps show where G.J. Lockbaum may publish in the future.

Co-authors

The 25 scholars most cited alongside G.J. Lockbaum, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with G.J. Lockbaum Line = papers co-authored together G.J. Lockbaum links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188 Viruses ·G.J. Lockbaum, Archie C. Reyes, Jeong Min Lee, Ronak Tilvawala, E.A. Nalivaika, Akbar Ali, Neşe Kurt Yılmaz, Paul R. Thompson, Celia A. Schiffer	2021	84
2	Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance Nature Communications ·Ala M. Shaqra, Sarah N. Zvornicanin, Qiu Yu J. Huang, G.J. Lockbaum, Mark Knapp, Laura Tandeske, David T. Bakan, Julia M. Flynn, Daniel N. Bolon, Stephanie Moquin, Dustin Dovala, Neşe Kurt Yılmaz, Celia A. Schiffer	2022	73
3	Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond Chemical Reviews ·Ashley N. Matthew, Florian Leidner, G.J. Lockbaum, M. Henes, Jacqueto Zephyr, Shurong Hou, Desaboini Nageswara Rao, Jennifer Timm, L.N. Rusere, Debra A. Ragland, Janet L. Paulsen, Kristina Prachanronarong, Djadé I. Soumana, E.A. Nalivaika, Neşe Kurt Yılmaz, Akbar Ali, Celia A. Schiffer	2021	50
4	Picomolar to Micromolar: Elucidating the Role of Distal Mutations in HIV-1 Protease in Conferring Drug Resistance ACS Chemical Biology ·M. Henes, G.J. Lockbaum, K. Kosovrasti, Florian Leidner, Gily S. Nachum, E.A. Nalivaika, Sook-Kyung Lee, E. Spielvogel, Shuntai Zhou, Ronald Swanstrom, Daniel N. Bolon, Neşe Kurt Yılmaz, Celia A. Schiffer	2019	32
5	Dual Inhibitors of Main Protease (M^Pro) and Cathepsin L as Potent Antivirals against SARS-CoV2 Journal of the American Chemical Society ·Santanu Mondal, Yongzhi Chen, G.J. Lockbaum, Sudeshna Sen, Sauradip Chaudhuri, Archie C. Reyes, Jeong Min Lee, Arshia N. Kaur, Nadia Sultana, Michael D. Cameron, Scott A. Shaffer, Celia A. Schiffer, Katherine A. Fitzgerald, Paul R. Thompson	2022	31
6	Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode Biochemistry ·G.J. Lockbaum, M. Henes, Jeong Min Lee, Jennifer Timm, E.A. Nalivaika, Paul R. Thompson, Neşe Kurt Yılmaz, Celia A. Schiffer	2021	28
7	Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease ACS Infectious Diseases ·G.J. Lockbaum, Florian Leidner, L.N. Rusere, M. Henes, K. Kosovrasti, Gily S. Nachum, E.A. Nalivaika, Akbar Ali, Neşe Kurt Yılmaz, Celia A. Schiffer	2018	27
8	HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2′ Ligands To Optimize Hydrogen Bonding in the Substrate Envelope Journal of Medicinal Chemistry ·L.N. Rusere, G.J. Lockbaum, Sook-Kyung Lee, M. Henes, K. Kosovrasti, E. Spielvogel, E.A. Nalivaika, Ronald Swanstrom, Neşe Kurt Yılmaz, Celia A. Schiffer, Akbar Ali	2019	22
9	Quinoxaline-Based Linear HCV NS3/4A Protease Inhibitors Exhibit Potent Activity against Drug Resistant Variants ACS Medicinal Chemistry Letters ·L.N. Rusere, Ashley N. Matthew, G.J. Lockbaum, Muhammad Jahangir, Alicia Newton, Christos J. Petropoulos, Wei Huang, Neşe Kurt Yılmaz, Celia A. Schiffer, Akbar Ali	2018	17
10	Inhibiting HTLV-1 Protease: A Viable Antiviral Target ACS Chemical Biology ·G.J. Lockbaum, M. Henes, Nathaniel Talledge, L.N. Rusere, K. Kosovrasti, E.A. Nalivaika, Mohan Somasundaran, Akbar Ali, Louis M. Mansky, Neşe Kurt Yılmaz, Celia A. Schiffer	2021	15
11	Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors mBio ·Ashley N. Matthew, Jacqueto Zephyr, Desaboini Nageswara Rao, M. Henes, Wasih Kamran, K. Kosovrasti, Adam K. Hedger, G.J. Lockbaum, Jennifer Timm, Akbar Ali, Neşe Kurt Yılmaz, Celia A. Schiffer	2020	14
12	Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance eLife ·E. Spielvogel, Sook-Kyung Lee, Shuntai Zhou, G.J. Lockbaum, M. Henes, Amy Sondgeroth, K. Kosovrasti, E.A. Nalivaika, Akbar Ali, Neşe Kurt Yılmaz, Celia A. Schiffer, Ronald Swanstrom	2023	13
13	Molecular Determinants of Epistasis in HIV-1 Protease: Elucidating the Interdependence of L89V and L90M Mutations in Resistance Biochemistry ·M. Henes, K. Kosovrasti, G.J. Lockbaum, Florian Leidner, Gily S. Nachum, E.A. Nalivaika, Daniel N. Bolon, Neşe Kurt Yılmaz, Celia A. Schiffer, Troy W. Whitfield	2019	12
14	Unique structural solution from a VH3-30 antibody targeting the hemagglutinin stem of influenza A viruses Nature Communications ·Wayne Harshbarger, Derrick Deming, G.J. Lockbaum, Nattapol Attatippaholkun, Maliwan Kamkaew, Shurong Hou, Mohan Somasundaran, Jennifer Wang, Robert W. Finberg, Quan Zhu, Celia A. Schiffer, Wayne A. Marasco	2021	11
15	HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues European Journal of Medicinal Chemistry ·G.J. Lockbaum, L.N. Rusere, M. Henes, K. Kosovrasti, Desaboini Nageswara Rao, E. Spielvogel, Sook-Kyung Lee, E.A. Nalivaika, Ronald Swanstrom, Neşe Kurt Yılmaz, Celia A. Schiffer, Akbar Ali	2023	6
16	Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere Journal of Medicinal Chemistry ·L.N. Rusere, G.J. Lockbaum, M. Henes, Sook-Kyung Lee, E. Spielvogel, Desaboini Nageswara Rao, K. Kosovrasti, E.A. Nalivaika, Ronald Swanstrom, Neşe Kurt Yılmaz, Celia A. Schiffer, Akbar Ali	2020	5
17	Abstract B073: Characterization of selective, allosteric inhibitors of human XRN1 Molecular Cancer Therapeutics ·G.J. Lockbaum, E. Allen Sickmier, Brian A. Sparling, Kevin E. Knockenhauer, Nicholas Holt, Julie Liu, Maureen M Lynes, Simina Grigoriu, Kenneth W. Duncan, Robert A. Copeland, P. Ann Boriack‐Sjodin	2023	3
18	Abstract A170: Discovery of small molecule inhibitors of ADAR1 Molecular Cancer Therapeutics ·Shane M. Buker, Stephen J. Blakemore, P. Ann Boriack‐Sjodin, Cindy Collins, Robert A. Copeland, Kenneth W. Duncan, Anna Ericsson, Alexandra Garadino, April Greene-Colozzi, Nathalie Léger, G.J. Lockbaum, Anugraha Raman, Scott Ribich, E. Allen Sickmier, Brian S Sparling, Jie Wu, Serena J. Silver	2023	2
19	Avoiding Drug Resistance by Substrate Envelope Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors The FASEB Journal ·Jacqueto Zephyr, Ashley N. Matthew, Desaboini Nageswara Rao, M. Henes, Wasih Kamran, Adam K. Hedger, G.J. Lockbaum, Jennifer Timm, Akbar Ali, Neşe Kurt Yılmaz, Celia A. Schiffer	2020	2
20	Optimizing the refinement of merohedrally twinned P6₁ HIV-1 protease–inhibitor cocrystal structures Acta Crystallographica Section D Structural Biology ·G.J. Lockbaum, Florian Leidner, William E. Royer, Neşe Kurt Yılmaz, Celia A. Schiffer	2020	1

About G.J. Lockbaum

G.J. Lockbaum is a scholar working on Infectious Diseases, Molecular Biology, Virology, Hepatology and Epidemiology, having authored 21 papers that have together received 448 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (10 papers), HIV Research and Treatment (7 papers), Hepatitis C virus research (7 papers), SARS-CoV-2 and COVID-19 Research (4 papers), RNA and protein synthesis mechanisms (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), interferon and immune responses (2 papers) and Computational Drug Discovery Methods (2 papers). The work is most often cited by research in Virology (87 citations), Infectious Diseases (250 citations), Computational Theory and Mathematics (167 citations), Hepatology (31 citations) and Organic Chemistry (86 citations). G.J. Lockbaum has collaborated with scholars based in United States. Frequent co-authors include Celia A. Schiffer, Neşe Kurt Yılmaz, E.A. Nalivaika, Akbar Ali, M. Henes, Paul R. Thompson, L.N. Rusere, Archie C. Reyes, Florian Leidner and Daniel N. Bolon. Their work appears in journals such as ACS Medicinal Chemistry Letters, Molecular Cancer Therapeutics, Nature Communications, Biochemistry and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact